Back to Articles
Clinical Topics
Featured

Pharmacology Deep Dive: Pressors and Inotropes—When to Choose Levo vs. Vaso vs. Epi

Understand the receptor pharmacology, hemodynamic effects, and clinical indications for common ICU vasopressors and inotropes. Make evidence-based choices at the bedside.

VitalJobs Editorial Team
January 20, 20265 min read
pharmacology
vasopressors
inotropes
norepinephrine
vasopressin
shock
5 min readUpdated February 4, 2026
Share:

Pharmacology Deep Dive: Pressors and Inotropes—When to Choose Levo vs. Vaso vs. Epi

You're titrating norepinephrine at 0.3 mcg/kg/min and the MAP is still 58. Do you go higher? Add vasopressin? Switch to epinephrine? The answer depends on understanding what each drug actually does.

Receptor Pharmacology Basics

Alpha-1 Receptors

  • Location: Vascular smooth muscle
  • Effect: Vasoconstriction
  • Clinical result: Increased SVR, increased MAP

Beta-1 Receptors

  • Location: Heart (primarily)
  • Effect: Increased contractility (inotropy), increased heart rate (chronotropy)
  • Clinical result: Increased cardiac output

Beta-2 Receptors

  • Location: Vascular smooth muscle, bronchial smooth muscle
  • Effect: Vasodilation, bronchodilation
  • Clinical result: Decreased SVR (at low doses), bronchodilation

Dopamine Receptors

  • Location: Renal, mesenteric, coronary vasculature
  • Effect: Vasodilation (at low doses)
  • Clinical result: Historical "renal dose dopamine" (now debunked)

V1 Receptors (Vasopressin)

  • Location: Vascular smooth muscle
  • Effect: Vasoconstriction (non-catecholamine pathway)
  • Clinical result: Increased SVR without direct cardiac effects

Drug-by-Drug Breakdown

Norepinephrine (Levophed)

Receptor Profile:

  • Strong alpha-1
  • Moderate beta-1
  • Minimal beta-2

Hemodynamic Effects:

  • ↑↑ SVR (vasoconstriction)
  • ↑ Contractility (mild)
  • ↔ or ↓ Heart rate (reflex bradycardia common)

Starting Dose: 0.05-0.1 mcg/kg/min Typical Range: 0.1-0.5 mcg/kg/min High Dose: >0.5 mcg/kg/min (consider adding second agent)

When to Use:

  • First-line for septic shock (Surviving Sepsis Campaign recommendation)
  • Distributive shock (vasodilation is the primary problem)
  • Most shock states as initial vasopressor

Cautions:

  • Peripheral ischemia at high doses
  • Arrhythmias (less than dopamine/epinephrine)
  • Tissue necrosis with extravasation

Vasopressin (ADH)

Receptor Profile:

  • V1 (vascular)
  • V2 (renal—not clinically significant at these doses)

Hemodynamic Effects:

  • ↑ SVR (via non-catecholamine pathway)
  • ↔ Heart rate
  • ↔ Contractility

Fixed Dose: 0.03-0.04 units/min (typically 0.04) Note: Unlike catecholamines, vasopressin is not titrated to effect

When to Use:

  • Second-line in septic shock (add to norepinephrine at 0.25-0.5 mcg/kg/min)
  • Catecholamine-sparing (may allow lower norepinephrine dose)
  • Vasoplegia post-cardiac surgery
  • Relative vasopressin deficiency in sepsis

Cautions:

  • Splanchnic vasoconstriction (gut ischemia risk)
  • Skin necrosis (rare)
  • Hyponatremia (V2 effects)

Why 0.04 units/min? Higher doses don't improve outcomes and increase ischemic complications.


Epinephrine

Receptor Profile:

  • Alpha-1 (especially at higher doses)
  • Strong beta-1
  • Strong beta-2

Hemodynamic Effects:

  • ↑ Contractility (strongest inotrope)
  • ↑ Heart rate
  • ↑ SVR at higher doses
  • ↓ SVR at very low doses (beta-2 predominates)

Starting Dose: 0.01-0.05 mcg/kg/min Typical Range: 0.05-0.3 mcg/kg/min Code Dose: 1 mg IV push (cardiac arrest)

When to Use:

  • Cardiogenic shock with hypotension (inotropy + vasoconstriction)
  • Anaphylaxis (bronchodilation + vasoconstriction + inotropy)
  • Cardiac arrest (ACLS protocol)
  • Septic shock with myocardial dysfunction
  • Severe bradycardia unresponsive to atropine

Cautions:

  • Tachyarrhythmias (most arrhythmogenic pressor)
  • Increased myocardial oxygen demand
  • Hyperglycemia
  • Lactic acidosis (beta-2 mediated—can confuse lactate trends)

Dopamine

Receptor Profile:

  • Dose-dependent:
    • Low dose (1-3 mcg/kg/min): Dopaminergic (renal vasodilation)
    • Medium dose (3-10 mcg/kg/min): Beta-1 (inotropy)
    • High dose (>10 mcg/kg/min): Alpha-1 (vasoconstriction)

When to Use (Limited):

  • Symptomatic bradycardia unresponsive to atropine (ACLS)
  • Rarely as first-line pressor (more arrhythmias than norepinephrine)

Why It's Fallen Out of Favor:

  • Higher arrhythmia risk than norepinephrine
  • "Renal dose dopamine" doesn't protect kidneys
  • No survival benefit over norepinephrine in septic shock

Phenylephrine (Neo-Synephrine)

Receptor Profile:

  • Pure alpha-1

Hemodynamic Effects:

  • ↑↑ SVR
  • ↔ or ↓ Contractility
  • ↓ Heart rate (reflex bradycardia)

When to Use:

  • Hypotension with tachyarrhythmias (when you can't tolerate beta effects)
  • Neurogenic shock (may be preferred)
  • Procedural hypotension (brief use)

Cautions:

  • Reflexive bradycardia can worsen cardiac output
  • Not ideal for cardiogenic shock (pure vasoconstriction without inotropy)

Dobutamine

Receptor Profile:

  • Strong beta-1
  • Moderate beta-2
  • Minimal alpha

Hemodynamic Effects:

  • ↑↑ Contractility
  • ↑ Heart rate
  • ↓ SVR (beta-2 vasodilation)

Starting Dose: 2.5 mcg/kg/min Typical Range: 5-20 mcg/kg/min

When to Use:

  • Cardiogenic shock with adequate blood pressure (pure inotropy needed)
  • Low cardiac output states
  • Often combined with norepinephrine (norepi for pressure, dobutamine for output)

Cautions:

  • Hypotension (vasodilation)
  • Tachyarrhythmias
  • Increased myocardial oxygen demand

Clinical Decision-Making by Shock Type

Septic Shock (Warm, Vasodilated)

  1. Norepinephrine first (vasoconstriction needed)
  2. Add vasopressin at 0.04 units/min when norepi 0.25-0.5 mcg/kg/min
  3. Consider epinephrine if echo shows poor cardiac function

Cardiogenic Shock (Cold, Vasoconstricted)

  • Hypotensive: Norepinephrine or epinephrine (need pressure and inotropy)
  • Normotensive: Dobutamine (pure inotropy without raising afterload)
  • Consider mechanical support (IABP, Impella) early

Anaphylaxis

  • Epinephrine IM (0.3-0.5 mg) first-line
  • Epinephrine infusion if persistent hypotension
  • Volume resuscitation critical

Neurogenic Shock (Spinal Cord Injury)

  • Loss of sympathetic tone → vasodilation + bradycardia
  • Norepinephrine or phenylephrine for SVR
  • May need atropine or chronotropic agents for bradycardia

Post-Cardiac Surgery Vasoplegia

  • Norepinephrine first
  • Vasopressin often effective
  • Methylene blue considered in refractory cases

Practical Tips

When to Add vs. Switch

  • Add vasopressin when norepi is working but you need more without escalating catecholamines
  • Add dobutamine when pressure is okay but cardiac output is low
  • Switch to epinephrine when you need strong inotropy AND vasoconstriction

Monitoring Response

  • MAP is not enough—assess perfusion (lactate, urine output, mental status)
  • Rising lactate on epinephrine may be drug-induced, not worsening shock

Weaning Pressors

  • General principle: Wean the most recently added agent first
  • Vasopressin is often weaned last (non-titrating, supports catecholamine weaning)
  • Wean slowly (10-20% decrements) with frequent reassessment

The Bottom Line

Pressor selection isn't one-size-fits-all. Understand the receptor pharmacology, assess the type of shock, and choose agents that address the underlying pathophysiology. Norepinephrine is first-line for most shock, but knowing when to add or switch makes you a more effective critical care provider.

Master the receptors, master the drugs, master the shock.

Found this article helpful? Share it with your colleagues.

Share: